Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
2.
Bertozzi S, Cedolini C, Londero AP, Baita B, Giacomuzzi F, Capobianco D, Tortelli M, Uzzau A, Mariuzzi L, Risaliti A (2019) Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: retrospective observational study. Medicine (Baltimore) 98(1):e13831CrossRef
3.
Yonekura R, Osako T, Iwase T, Ogiya A, Ueno T, Kitagawa M, Ohno S, Akiyama F (2019) Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 174(1):103–111CrossRefPubMed
Metadata
Title
Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision?
Authors
Darko Zdravkovic
Nebojsa Ivanovic
Bogdan Crnokrak
Publication date
01-08-2019
Publisher
Springer US
Keyword
Metastasis
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05269-x

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Preclinical study

T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer

Review

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

Epidemiology

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

Review

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

Epidemiology

Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy

Clinical trial

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits